Clinical Trials
Updated 10/30/2009Search for Clinical Trials using ClinicalTrials.gov
Novartis ATI355 in Patients With Acute Spinal Cord Injury. Previously this study was not recruiting patients in the United States but, as of September 2009, Methodist Hospital System located in Houston, Texas is listed as a recruiting site. Clinical Trial Info
Geron
October 30th, 2009. Geron Corporation today announced the company's plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury. The plan is expected to enable Geron to re-initiate the Phase I clinical trial of GRNOPC1 in patients with complete thoracic spinal cord injury and to support future expansion of the trial to patients with cervical injuries.
GlaxoSmithKline
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke. This study is ongoing but not currently recruiting patients.
Alseres Pharmaceuticals
Cethrin - for the treatment of acute spinal cord injury. The phase I/II trial has been completed and Cethrin was well tolerated. A phase II trial is currently planned to start in October 2009.
Spinal Cord Injury Network USA (SCINetUSA)
SCINetUSA evolved from the efforts of Dr. Wise Young of Rutgers University after his successful establishment of ChinaSCINet clinical trials network. You can help support the SCINetUSA trial by visiting Just a Dollar Please website.
ReNeuron Group
ReNeuron is currently working towards commencement of clinical trials for its REN001 stem cell therapy for ischaemic stroke.
Novagenesis
Novagenesis' RMx regenerative matrix been in development for several years but has yet to move into clinical trials. The company has not released any new information about its plans and it is uncertain if or when they will be ready to initiate clinical trials.
XenoPort
Jun. 30, 2009 - XenoPort announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study. AP was well tolerated during the tria.
Allergan
Allegan is conductiong a clinical trial for the safety and efficacy of botulinum toxin type A (Botox) for the treatment of neurogenic overactive bladder in patients with a spinal cord injury or multiple sclerosis. Additionally, a long term followup clinical trial of botulinum toxin type A (Botox) for neurogenic overactive bladder is also being conducted. Clinical Trial Info
Tengion
Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury Clinical Trial Info
Safety of Riluzole in Patients With Acute Spinal Cord Injury
The primary aim of the study is to develop acute care safety and pharmacokinetic profiles of riluzole in patients who have sustained a acute traumatic spinal cord injury. Secondary objectives are to conduct exploratory analyses of functional outcomes for purposes of planning a subsequent Phase II randomized study of the efficiency of Riluzole for the treatment of acute traumatic spinal cord injury.
China Spinal Cord Injury Network Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries.
Clinical Trial Info
Taipei Veterans General Hospital-Interpositional nerve grafts in combination with fibroblast growth factor (FGF).
This trial is the result of an initial phase 1 human clinical trial involving fibroblast growth factors used alone in patients with cervical spinal cord injury. According to the author of this paper, a study involving FGF and nerve grafts is ongoing at Taipei Veterans General Hospital. This study involves patients with completely transected spinal cords.